Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

13.9%

5 terminated/withdrawn out of 36 trials

Success Rate

84.8%

-1.7% vs industry average

Late-Stage Pipeline

22%

8 trials in Phase 3/4

Results Transparency

100%

28 of 28 completed trials have results

Key Signals

2 recruiting28 with results

Enrollment Performance

Analytics

Phase 2

24(66.7%)

Phase 3

6(16.7%)

Phase 1

4(11.1%)

Phase 4

2(5.6%)

36Total

Phase 2(24)

Phase 3(6)

Phase 1(4)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials

NCT06648434Phase 1Recruiting

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT06374459Phase 1Recruiting

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Role: collaborator

NCT07011706Phase 2Active Not Recruiting

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT06585202Phase 2Completed

Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

Role: lead

NCT05216224Phase 2Completed

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Role: lead

NCT05511519Phase 2Terminated

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Role: lead

NCT05432596Phase 2Completed

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Role: lead

NCT05279417Phase 2Completed

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Role: lead

NCT05791474Phase 1Withdrawn

ATI-2231 in Advanced Solid Tumor Malignancies

Role: collaborator

NCT04598269Phase 2Completed

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Role: lead

NCT04524858Phase 2Terminated

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Role: lead

NCT04247815Phase 2Completed

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Role: lead

NCT03495817Phase 2Completed

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Role: lead

NCT02260180Phase 2Completed

Study of A-101 for the Treatment of Seborrheic Keratosis

Role: lead

NCT03468855Phase 2Completed

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Role: lead

NCT03812510Phase 3Completed

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Role: lead

NCT03691831Phase 3Completed

A Study of A-101 Topical Solution for the Treatment of Common Warts

Role: lead

NCT03759340Phase 2Terminated

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Role: lead

NCT03687372Phase 3Completed

Study of A-101 Topical Solution for the Treatment of Common Warts

Role: lead

NCT03594227Phase 2Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Role: lead